Literature DB >> 16232327

Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study.

Ding-Fen Han1, Xin Zhou, Ming-Bai Hu, Wei Xie, Zong-fu Mao, Dong-e Chen, Fang Liu, Fang Zheng.   

Abstract

BACKGROUND: Endogenous estrogen plays a very important role in the carcinogenesis and progression of breast cancer. The enzymes involved in the biosynthesis and metabolism of estrogen have been proposed to contribute to this effect. To examine this hypothesis, we conducted a case-control study to investigate the relationship between polymorphisms of genes responsible for estrogen biosynthesis (CYP17, cytochrome P450c17a and CYP19, aromatase cytochrome P450) and estrogen sulfation of inactivation (SULT1A1, sulfotransferase1A1) and the risk of breast cancer in Chinese women.
METHODS: This study involved 213 breast cancer patients and 430 matched controls. PCR-based restriction fragment length polymorphism (RFLP) and short tandem repeat polymorphism (STRP) assays were used to detect the mononucleotide transition of CYP17 and SULT1A1 and tandem repeat polymorphism of CYP19. Logistic regression analyses were used to determine OR and 95% CI of each and all three high-risk genotypes, of all three genotypes combined, and of estrogen exposure factors. The relationship between each high-risk genotype and clinicalpathological characteristics were also assessed.
RESULTS: The frequency of A2 allele of CYP17 was 49.8% in cases and 49.1% in controls (P = 0.82). The frequency of His allele of SULT1A1 was significantly higher in cases (13.6%) than in controls (9.5%) (P < 0.05). There was also significant difference of the (TTTA) 10 allele of CYP19 which was 12.4% in cases and 8.2% in controls (P < 0.05). When the CYP17 A2 allele, CYP19 (TTTA) 10 and SULT1A1 His allele were considered as the "putative high-risk" genotype, there was an increased risk of breast cancer with the number of high-risk genotypes in a dose-response effect (trend, P = 0.05). In multivariate analysis, the SULT1A1 genotype remained the most significant determinant for breast cancer, with OR = 2.37 (95% CI 1.23-4.74), followed by CYP19, with OR = 1.75 (95% CI 1.27-3.56). The (TTTA) 10 allele of CYP19 was associated with tumor size, and the His allele of SULT1A1 associated with status of lymph node metastasis.
CONCLUSIONS: This study supports the hypothesis that breast cancer can be initiated by estrogen exposure and that estrogen metabolizing genes are involved in this mechanism. This multigenic model is useful for identifying individuals who are at higher risks of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16232327

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  12 in total

Review 1.  Regulation of the human catalytic subunit of telomerase (hTERT).

Authors:  Michael Daniel; Gregory W Peek; Trygve O Tollefsbol
Journal:  Gene       Date:  2012-02-13       Impact factor: 3.688

2.  Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.

Authors:  Lori C Sakoda; Christie Blackston; Jennifer A Doherty; Roberta M Ray; Ming Gang Lin; Helge Stalsberg; Dao Li Gao; Ziding Feng; David B Thomas; Chu Chen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-05       Impact factor: 4.254

3.  Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.

Authors:  Chu Chen; Lori C Sakoda; Jennifer A Doherty; Melissa M Loomis; Sherianne Fish; Roberta M Ray; Ming Gang Lin; Wenhong Fan; Lue Ping Zhao; Dao Li Gao; Helge Stalsberg; Ziding Feng; David B Thomas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

4.  Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression.

Authors:  Jean-Philippe Emond; Louis Lacombe; Patrick Caron; Véronique Turcotte; David Simonyan; Armen Aprikian; Fred Saad; Michel Carmel; Simone Chevalier; Chantal Guillemette; Eric Lévesque
Journal:  Br J Cancer       Date:  2021-04-07       Impact factor: 7.640

5.  Plasma Leptin, hTERT Gene Expression, and Anthropometric Measures in Obese and Non-Obese Women with Breast Cancer.

Authors:  Mohammad Rahmati-Yamchi; Nosratallah Zarghami; Mohammad Rahbani; Ali Montazeri
Journal:  Breast Cancer (Auckl)       Date:  2011-03-01

6.  Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers.

Authors:  Adel M A Assiri; Hala F M Kamel; Mohamed F R Hassanien
Journal:  Dis Markers       Date:  2015-03-08       Impact factor: 3.434

7.  Investigation of prognostic value of polymorphisms within estrogen metabolizing genes in Lithuanian breast cancer patients.

Authors:  Aistė Savukaitytė; Rasa Ugenskienė; Roberta Jankauskaitė; Darius Čereškevičius; Eglė Šepetauskienė; Elona Juozaitytė
Journal:  BMC Med Genet       Date:  2015-02-04       Impact factor: 2.103

8.  Association between CYP17 T-34C rs743572 and breast cancer risk.

Authors:  Jing Sun; Hong Zhang; Meiyan Gao; Zhishu Tang; Dongyan Guo; Xiaofei Zhang; Zhu Wang; Ruiping Li; Yan Liu; Wansen Sun; Xi Sun
Journal:  Oncotarget       Date:  2017-12-26

Review 9.  Sulfonation, an underexploited area: from skeletal development to infectious diseases and cancer.

Authors:  Ada W. Y. Leung; Ian Backstrom; Marcel B Bally
Journal:  Oncotarget       Date:  2016-08-23

10.  Case-control study and meta-analysis of SULT1A1 Arg213His polymorphism for gene, ethnicity and environment interaction for cancer risk.

Authors:  A Kotnis; S Kannan; R Sarin; R Mulherkar
Journal:  Br J Cancer       Date:  2008-10-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.